Latest National Institute for Health and Clinical Excellence Stories
BRIDGEWATER, N.J., Sept.
Professor Karol Sikora said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years.He calculated they could cost the NHS 50bn around half the current budget, which tops 100bn.The professor, who is director of Cancer Partners UK, a private provider of cancer services that works with the NHS, came up with the figures for Sky News.He said: "50bn is the equivalent to raising tax by 15p for...
By Jane Kirby THE high cost of cancer drugs could lead the NHS into "meltdown", a leading expert said today. Professor Karol Sikor a said the next generation of drugs would keep people alive for longer but they were so expensive they could swallow half of the current NHS budget within four years.
By Helen Puttick IT is, perhaps, an unusual move; from an organisation which fought for patients to one that often faces accusations of acting against their interests.
By Sadie Gray A cancer sufferer whose primary care trust refused to pay for a drug which could extend his life by up to three years has launched an "end of the road" legal challenge to the decision.
With the cost of healthcare provision spiraling, governments and payers across the seven major markets are applying cost-cutting measures, putting even greater pressure on pharmaceutical companies.
According to charity Infertility Network UK, North Staffordshire PCT is one of just three health authorities across the country which has suspended funding for IVF. The charity says 92 PCTs fund one cycle of treatment, 32 fund two and nine fund three cycles.
DR McGONAGLE'S put-down of NICE (Letters, August 28) as the "National Institute of Complete Embarrassment" does a disservice. NICE has produced final guidance for the drug Lucentis, now accepted for use throughout the UK.
The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration.
By Paul Greaves A war veteran who fought a campaign to get a sight-saving drug on the NHS says he feels "vindicated" it will now be made freely available across the country.